<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477035</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-00245</org_study_id>
    <secondary_id>95889</secondary_id>
    <secondary_id>BMT173</secondary_id>
    <nct_id>NCT00477035</nct_id>
  </id_info>
  <brief_title>Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies</brief_title>
  <official_title>A Phase I Study of Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for the Treatment of High-risk Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sally Arai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to conduct a phase I study of adoptive immunotherapy with
      autologous, ex-vivo expanded cytokine-induced killer (CIK) cells to reduce the relapse rate
      in autologous stem cell transplant patients with high-risk hematologic malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disease relapse remains the major cause of treatment failure in autologous stem cell
      transplantation for patients with high-risk disease. Relapse after autologous transplant is
      in part due to the persistence of residual cancer cells. Cellular immunotherapy using
      activated autologous effector cells to recognize and kill tumor targets in a minimal disease
      state after transplant is a strategy being explored to reduce relapse and improve survival.
      We hypothesize that cytokine-induced killer (CIK) cell-based immunotherapy can reduce the
      relapse rate after high-risk autologous stem cell transplantation by treating post-transplant
      minimal residual disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To document the toxicities of infusion of autologous CIK cells</measure>
    <time_frame>Day 42 post autologous stem cell transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure freedom from progression (FFP)</measure>
    <time_frame>1 and 2 years post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure event free survival</measure>
    <time_frame>1 and 2 years post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure overall survival</measure>
    <time_frame>1 and 2 years post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure disease response</measure>
    <time_frame>at day 40-60, day 90, day 180, and yearly</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Autologous Cytokine-induced Killer Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIK cells</intervention_name>
    <description>2x10e8 cells/kg</description>
    <arm_group_label>Autologous Cytokine-induced Killer Cells</arm_group_label>
    <other_name>autologous cytokine-induced killer cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>60 mg/kg</description>
    <arm_group_label>Autologous Cytokine-induced Killer Cells</arm_group_label>
    <other_name>Eposin</other_name>
    <other_name>Etopophos</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bcnu</intervention_name>
    <description>15 mg/kg</description>
    <arm_group_label>Autologous Cytokine-induced Killer Cells</arm_group_label>
    <other_name>Carmustine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>100 mg/kg</description>
    <arm_group_label>Autologous Cytokine-induced Killer Cells</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>cytophosphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>1250 mg/m2</description>
    <arm_group_label>Autologous Cytokine-induced Killer Cells</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
    <description>30 mg/m2</description>
    <arm_group_label>Autologous Cytokine-induced Killer Cells</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>200 mg/m2</description>
    <arm_group_label>Autologous Cytokine-induced Killer Cells</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>Melphalan hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18 and 75 years of age, inclusive candidates for standard autologous
             SCT who are at high risk for relapse:

               -  Acute myelogenous leukemia (AML), high risk, in CR1 or beyond without a donor
                  (CR1 defined as: normal bone marrow morphology, resolution of any previously
                  abnormal karyotype, neutrophils &gt; 1000/ul, platelets &gt; 100,000/ul, independence
                  from red cell transfusion, no evidence extramedullary leukemia)

               -  Hodgkin's lymphoma relapsed or refractory, with the presence of &gt;= 1 adverse risk
                  factor (Adverse risk factors are defined as stage IV involvement of the lung or
                  bone marrow, constitutional symptoms, and the presence of more than minimal
                  residual disease before the preparatory regimen)

               -  Multiple myeloma with high risk features with only single autologous transplant
                  option. High risk features defined as IgA myeloma, B2M &gt; 2.5 mg/ml with normal
                  kidney function, complex karyotypes or isolated chromosome 13 abnormalities,
                  standard-dose therapy &gt; 12 months, or inability to achieve at least 50% reduction
                  of plasma cells in the bone marrow or 50% reduction in the paraprotein
                  concentration after initial induction chemotherapy prior to transplant.

          -  Patients must have ECOG performance status &lt; 2

          -  Patients must have adequate renal function with a serum creatinine of &lt; 2 mg/dl or
             creatinine clearance &gt; 50 ml/min.

          -  Patients must have adequate liver function with a total bilirubin &lt; 2 mg/dl or
             transaminases &lt; 3 times the upper limit of normal.

          -  Patients must have negative antibody serology for human immunodeficiency virus (HIV1
             and 2)

          -  Adult women and minorities will be included. Patients with childbearing potential must
             use effective contraception.

          -  Patients must sign informed consent prior to initiation of any study-related
             treatments.

        Exclusion Criteria:

          -  ECOG performance status &gt; 2

          -  LVEF &lt; 45%

          -  Pulmonary diffusion capacity &lt; 50% predicted

          -  Total bilirubin &gt; 2 mg/dl

          -  Creatinine &gt; 2 mg/dl

          -  Pregnancy

          -  Patients positive for HIV

          -  Patients with engraftment failure at day 42 post transplant defined as failure to
             achieve a granulocyte count &gt; 500/ul on 3 successive daily determinations and an
             unsupported platelet count of &gt;= 50,000/ul by day 42

          -  Patients with active, uncontrolled infection that is expected to continue beyond day
             42-63.

          -  Patients who fail to collect sufficient quantities of stem cells (&gt; 1.6 x 10^9 cells)
             during apheresis to support CIK cell expansion cultures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sally Arai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sally Arai</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

